Drug intelligence / Profile preview

E7820 + FOLFIRI

Development stage: Discontinued
Lead developer: Eisai
Modality: Small Molecules
Administration: Intravenous

Overview

E7820 + FOLFIRI is a combination therapy consisting of E7820 and the FOLFIRI chemotherapy regimen. FOLFIRI is a standard chemotherapy combination that includes folinic acid (leucovorin), fluorouracil (5-FU), and irinotecan. This combination was investigated for the treatment of locally advanced or metastatic colorectal cancer, particularly as a second-line therapy.

Targets

ITGA2 (Integrin alpha-2)TS (Thymidylate synthase)TOP1 (DNA Topoisomerase I)ANTXR2 (Anthrax toxin receptor 2)

Beyond the preview

Go deeper on E7820 + FOLFIRI.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on E7820 + FOLFIRI.

Explore the full profile